96842 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
Sub-classes:POLYPEPTIDE SCAFFOLD
#2COMPOSITIONS AND METHODS FOR MAKING ANTIBODY CONJUGATES
#3Novel Genetic Tools
#4BACTERIUM WITH REDUCED SENSITIVITY TO BACTERIOPHAGE
#5PROTEIN, POLYNUCLEOTIDE, EXPRESSION VECTOR, TRANSFORMANT, PLASMALOGEN-CONTAINING COMPOSITION, AND METHOD FOR PRODUCING PLASMALOGEN
#6Genome Engineering
#7FUSION PROTEIN AND VACCINE
#8BIOTECHNOLOGICAL PRODUCTION OF COLLAGEN PROTEINS AND BACTERIAL COLLAGEN-LIKE PROTEINS BY RECOMBINANT MICROORGANISMS
#9STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDES AND IMMUNOGENIC CONJUGATE THEREOF
#10POLYPEPTIDE AND ITS USE IN AFFINITY PURIFICATION
#11POLYPEPTIDES BINDING TO HUMAN COMPLEMENT C5
#12MODIFIED MICROORGANISMS EXPRESSING SagA AND RELATED COMPOSITIONS FOR IMMUNOMODULATION AGAINST INFECTION AND CANCER IMMUNOTHERAPY
#13MULTIVALENT PROTEINS AND SCREENING METHODS
#14STREPTOCOCCUS SUIS VACCINE COMPOSITION COMPRISING IMMUNOGENIC FUSION POLYPEPTIDES
#15METHODS AND COMPOSITIONS WITH ANTIFUNGAL ACTIVITY
#16NEW LACTIC ACID BACTERIA
#17ENTEROCOCCUS PORE-FORMING TOXINS AND METHODS OF USE THEREOF
#18NEW LACTIC ACID BACTERIA
#19LANTHIPEPTIDES AND METHODS OF USE
#20AN ISOLATED S. SALIVARIUS STRAIN AND ITS USE AS AN ANTIMICROBIAL PRODUCING PROBIOTIC
#21IMMUNOGENIC FUSION PROTEIN
#22METHODS, KITS, AGENTS AND APPARATUSES FOR TRANSDUCTION
#23EFFECT OF GB1 DOMAIN FUSION ON UPREGULATION OF RECOMBINANT PROTEIN EXPRESSION IN PLANT
#24Methods and compositions for assessing antibody specificities
#25ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)
#26MOLECULAR PEPTIDE MUTANT WITH A HIGH ESTER BOND FORMATION EFFICIENCY
#27OFF THE SHELF PROXIMITY BIOTINYLATION ENZYME
#28ORAL VACCINE VIA DENTAL BACTERIA AND EMITTED PEPTIDES TO PREVENT INFECTION FROM A PATHOGEN
#29REPEAT-CHAIN FOR THE PRODUCTION OF DIMER, MULTIMER, MULTIMER COMPLEX AND SUPER-COMPLEX
#30REPEAT-CHAIN FOR THE PRODUCTION OF DIMER, MULTIMER, MULTIMER COMPLEX AND SUPER-COMPLEX
#31HIGH-AFFINITY SUPRAMOLECULAR POLYMERS FOR BINDING-TRIGGERED ANTIBODY PRECIPITATION AND PURIFICATION
#32IMMUNOEVASIVE ANTI-TUMOR ADENOVIRUS
#33METHOD FOR THE PRODUCTION OF A DAIRY FOOD PRODUCT AND A METHOD FOR GENE TRANSFER BY CONJUGATION
#34METHODS AND COMPOSITIONS THEREOF FOR SITE-SPECIFIC LABELING OF HUMAN IgG BY PROXIMITY-BASED SORTASE-MEDIATED LIGATION
#35LACTIC ACID BACTERIA COMPOSITION FOR PREPARING FERMENTED PRODUCTS
#36STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDES AND IMMUNOGENIC CONJUGATE THEREOF
#37POLYPEPTIDES THAT INTERACT WITH PEPTIDE TAGS AT LOOPS OR TERMINI AND USES THEREOF
#38IMMUNOGENIC FUSION PROTEIN
#39SITE-SPECIFIC BIO-CONJUGATION METHODS AND COMPOSITIONS USEFUL FOR NANOPORE SYSTEMS
#40TARGETED DNA DEMETHYLATION AND METHYLATION
#41LACTIC ACID BACTERIA COMPOSITION FOR PREPARING FERMENTED PRODUCTS
#42Attenuating bacterial virulence by attenuating bacterial folate transport
#43Methods and compositions for assessing antibody specificities
#44Affinity Chromatography Ligands with Mild Elution pH
#45HIGHER PERFORMANCE PROTEASES FOR SCARLESS PEPTIDE TAG REMOVAL
#46COMPOSITIONS AND METHODS INVOLVING PROBIOTIC MOLECULES
#47ORAL VACCINE, METHOD OF PREPARATION AND USE THEREOF
#48MOLECULAR PEPTIDE MUTANT
#49PURIFICATION PROCESSES FOR POLYSACCHARIDES AND POLYPEPTIDE CONJUGATES THEREOF
#50A NOVEL PROBIOTIC STREPTOCOCCUS SALIVARIUS STRAIN AND ITS USES
#51STREPTOCOCCAL GlcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
#52IMMUNOGENIC PEPTIDE AGAINST GROUP A STREPTOCOCCUS
#53METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIES
#54FLUORESCENT PROTEIN SENSOR CAPABLE OF QUANTITATIVELY MEASURING OXIDATION DEGREE OF METHIONINE RESIDUES OF SPECIFIC PROTEIN, AND USE THEREOF
#55PHARMACEUTICAL COMBINATION AND USE THEREOF
#56ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY
#57PEPTIDE TAGS AND BINDING PARTNERS
#58Methods of Modulating Expression of Target Nucleic Acid Sequences in A Cell
#59GBS FERRITIN NANOPARTICLES
#60CRISPR/CAS FUSION PROTEINS AND SYSTEMS
#61BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSIN
#62METHOD OF INCREASING NISIN PRODUCTION IN LACTOCOCCUS LACTIS
#63ACETYLCHOLINE MODULATION OF IMMUNE FUNCTION
#64Bacteriocin Production, Compositions and Methods of Use
#65METHODS AND COMPOSITIONS RELATING TO CHIMERIC ANTIGEN RECEPTORS
#66Glycoconjugation process
#67IMMUNOGENIC COMPLEX FOR ELICITING PROTECTIVE IMMUNITY AGAINST GROUP B STREPTOCOCCUS
#68OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS
#69QUANTITATIVE CONTROL OF ACTIVITY OF ENGINEERED CELLS EXPRESSING SPYCATCHER AND SPYTAG UNIVERSAL IMMUNE RECEPTORS
#70Immunogenic composition
#71CAS9 VARIANTS AND USES THEREOF
#72COMPOSITIONS AND METHODS FOR MAKING ANTIBODY CONJUGATES
#73RAPID PRODUCTION OF BISPECIFIC ANTIBODIES FROM OFF-THE-SHELF IGGS WITH HIGH YIELD AND PURITY
#74SKELETAL MYOBLAST PROGENITOR CELL LINEAGE SPECIFICATION BY CRISPR/CAS9-BASED TRANSCRIPTIONAL ACTIVATORS
#75PORCINE CIRCOVIRUS TYPE 2 VLP VACCINE
#76Immunogenic fusion protein
#77ACETYLCHOLINE MODULATION OF IMMUNE FUNCTION
#78Methods, kits, agents and apparatuses for transduction
#79MODIFIED VIRAL PARTICLES AND USES THEREOF
#80Genome Engineering
#81GBD-SSTad-SSTad recombinant protein and method for producing and using same
#82Attenuating bacterial virulence by attenuating bacterial folate transport
#83METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN
#84Modified microorganisms expressing saga and related compositions for immunomodulation against infection and cancer immunotherapy
#85METHODS AND COMPOSITIONS FOR ASSESSING PROTEIN FUNCTION
#86POLYPEPTIDE WITH ENHANCED RATE OF SPONTANEOUS ISOPEPTIDE BOND FORMATION WITH ITS PEPTIDE TAG PARTNER AND USES THEREOF
#87Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof
#88Vaccine against infection
#89Polypeptide and its use in affinity purification
#90Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)
#91Lactic acid bacteria
#92Internal protein tags
#93Polypeptides binding to human complement C5
#94Modified bacterial microcompartment shell protein
#95virulence factor compositions
#96Glycoconjugation process
#97Method for the production of a dairy food product and a method for gene transfer by conjugation
#98STREPTOCOCCAL TOXIC SHOCK SYNDROME
#99ENHANCED PRODUCTION OF IMMUNOGLOBULINS
#100BOTULINUM TOXIN CELL BINDING DOMAIN POLYPEPTIDES AND METHODS OF USE FOR TREATMENTS OF FIBROSIS ASSOCIATED DISORDERS
#101Compositions including probiotic bacteria for the expression and secretion of enterocins to control clostridia perfringens-induced necrotic enteritis in livestock and related methods
#102Site-specific bio-conjugation methods and compositions useful for nanopore systems
#103Acinetobacter O-oligosaccharyltransferases and uses thereof
#104CAS9 VARIANTS AND USES THEREOF
#105Streptococcal GlcNAc-lacking glycopolypeptides, cell wall carbohydrates, vaccines, and methods for making and using them
#106CRISPR/Cas fusion proteins and systems
#107Methods and compositions for assessing antibody specificities
#108capsular polysaccharides and immunogenic conjugate thereof
#109Fusion protein containing trail and IgG binding domain and the uses thereof
#110Immunogenic complex for eliciting protective immunity against group B
#111Dynamically-adaptive live therapeutic agents and methods of use thereof
#112Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
#113Diagnostic test
#114Immunogenic peptide against group a
#115Methods and compositions for assessing protein function
#116Display of heterologous molecules on bacterial cells and membrane vesicles
#117Glycoconjugation process
#118Modified streptolysin O
#119METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN
#120CRISPR/Cas fusion proteins and systems
#121neurotoxin (BoNT/EN) and derivatives thereof
#122Method for the production of a dairy food product and a method for gene transfer by conjugation
#123virulence factor compositions
#124Modified lantibiotics and methods of making and using the modified lantibiotics
#125Anti-CRISPR polynucleotides and polypeptides and methods of use
#126Nanonets and spherical particles
#127Immunogenic composition
#128Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)
#129Adenovirus comprising an albumin-binding moiety
#130ANALYTICAL AND THERAPEUTIC METHODS AND COMPOSITIONS, AND USES THEREOF
#131Proteins increasing pancreatic β cell number and methods of use
#132Modified gram positive bacteria and uses thereof
#133Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof
#134Modified bacterial microcompartment shell proteins
#135Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#136Targeted DNA demethylation and methylation
#137Bacteriocin production, compositions and methods of use
#138Anti-CRISPR genes and proteins and methods of use
#139Methods, kits, agents and apparatuses for transduction
#140Biofilm prevention, disruption and treatment with bacteriophage lysin
#141Methods of modulating expression of target nucleic acid sequences in a cell
#142POLYPEPTIDES
#143Affinity chromatography ligands with mild elution pH
#144Methods and compositions for assessing antibody specificities
#145Internal protein tags
#146Acinetobacter o-oligosaccharyltransferases and uses thereof
#147Glycoconjugation process
#148Cholera toxin chimera and its use as a staph vaccine
#149Bacteria
#150LANTIBIOTIC VARIANTS AND USES THEREOF
#151Dendritic-cell-targeted peptide, fusion peptide utilizing said peptide, and vaccine utilizing said fusion peptide
#152Immunogenic complex for eliciting protective immunity against group b streptococcus
#153ARTIFICIALLY ENGINEERED SC FUNCTION CONTROL SYSTEM
#154Group A streptococcus vaccine
#155vaccines to protect against reproductive, nursery-age, and growing pig diseases and methods of making and use thereof
#156PNEUMOCOCCAL INHIBITORY FACTOR COMPOSITIONS AND METHODS OF USE THEREOF
#157Modified microorganisms expressing SagA as anti-infective agents, probiotics and food components
#158Bacterial inhibitors
#159SINGLE GUIDE RNA/CRISPR/CAS9 SYSTEMS, AND METHODS OF USE THEREOF
#160Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
#161Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
#162Polypeptides binding to human complement C5
#163USE OF HIGH AFFINITY MONOCLONAL ANTIBODY PRODUCT BINDERS TO INCREASE THE DURATION OF ACTION OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN A BIOLOGIC TISSUE
#164Stabilization of biomimetic membranes
#165ORAL ADMINISTRATION
#166Tandemly repeated antibody-binding protein and its applications
#167Site-specific bio-conjugation methods and compositions useful for nanopore systems
#168Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#169LIPIDATED STREPTOCOCCUS PNEUMONIAE ANTIGEN COMPOSITIONS, METHODS OF PREPARATION AND USE
#170Methods and compositions relating to chimeric antigen receptors
#171Compositions and methods for making antibody conjugates
#172CRISPR-associated (Cas) proteins with reduced immunogenicity
#173Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity
#174Immunogenic fusion protein
#175Immunoglobulin-binding polypeptide
#176Use of immunomodulatory kits for immunotherapeutic treatment of patients with myeloid leukemias
#177HU specific interfering agents
#178Methods for non-covalent Fc-domain-containing protein display on the surface of cells and methods of screening thereof
#179Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
#180Cholera toxin chimera and its use as a staph vaccine
#181Methods and compositions for assessing antibody specificities
#182Modified gram positive bacteria and uses thereof
#183Dynamically-adaptive live therapeutic agents and methods of use thereof
#184Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)
#185protein antigen, and preparation method and use thereof
#186Immunogenic compositions containing bacterial outer membrane vesicles
#187Vaccine against infection
#188Modified lantibiotics and methods of making and using the modified lantibiotics
#189Targeted RNA knockdown and knockout by type III-A Csm complexes
#190Lactococcus lactis producing TSLP or IL-25 and their uses as probiotics and therapeutics
#191Nucleic acids and proteins from streptococcus groups A and B
#192PROTEIN EXPRESSION ENHANCING POLYPEPTIDES
#193METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN
#194Polypeptides binding to human complement C5
#195Acinetobacter O-oligosaccharyltransferases and uses thereof
#196Methods and compositions for RNA-directed target DNA modification
#197Methods and compositions involving protein G variants
#198Cholera toxin chimera and its use as a staph vaccine
#199Mutant immunoglobulin K chain variable region-binding peptide
#200Non-natural consensus albumin binding domains
#201Methods and pharmaceutical compositions for the treatment of ischemic conditions
#202Lipidated antigen compositions, methods of preparation and use
#203NISIN-BASED COMPOUNDS AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS
#204Modified Fab region-binding peptide
#205AFFINITY SEPARATION MATRIX FOR FAB REGION-CONTAINING PEPTIDE
#206Affinity separation matrix for purifying protein containing immunoglobulin K chain variable region
#207Biosensor system for the rapid detection of analytes
#208Biosensor system for the rapid detection of analytes
#209Biosensor system for the rapid detection of analytes
#210Fab REGION-BINDING PEPTIDE
#211GENETIC DETECTION PLATFORM
#212Method for knock-in of DNA into target region of mammalian genome, and cell
#213Conjugation of capsular saccharides
#214HIGHER PERFORMANCE PROTEASES FOR SCARLESS TAG REMOVAL
#215Enhanced production of immunoglobulins
#216Programmable RNA shredding by the type III-A CRISPR-Cas system of
#217Streptococcal GlcNac-lacking gylcopolypeptides, cell wall carbohydrates, vaccines, and methods for making and using them
#218Peptide tag system that spontaneously form an irreversible link to protein partners via isopeptide bonds
#219Serum half-life extension using IgBD
#220Anti-Tumor Necrosis Factor-Alpha Agents And Uses Thereof
#221METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN
#222Extracellular hyaluronidase from
#223Purification of secreted polysaccharides from S. agalactiae
#224Removal of impurities from protein A eluates
#225Adenovirus comprising an albumin-binding moiety
#226EXPRESSION OF TRIPLE-HELICAL COLLAGEN-LIKE PRODUCTS IN E.COLI
#227Group A vaccine
#228Diagnostic test of infections
#229Bacteriocin with novel activity
#230Immunogenic proteins and compositions
#231Vaccine and therapeutic delivery system
#232Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#233Selectively targeted antimicrobial peptides and the use thereof
#234STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS
#235Polypeptides targeting glycosylated MUC2 proteins, methods of synthesis, their nucleic acids and uses thereof
#236Chemically modified graphene
#237Stable polypeptides binding to human complement C5
#238Engineered albumin binding polypeptide
#239Methods and compositions for the display of polypeptides on the pili of Gram-positive bacteria
#240Biosensor system for the rapid detection of analytes
#241Fab region-binding peptide
#242PROTEIN COMPRISED BY LINKING BY LINKER MULTIPLE DOMAINS HAVING AFFINTIY FOR PROTEINS HAVING Fc PART OF IMMUNOGLOBULIN G (IgG)
#243METHODS FOR REDUCING DEVELOPMENT OF RESISTANCE TO ANTIBIOTICS
#244Nucleic acids and proteins from streptococcus groups A and B
#245Protein-polymer complex, TGase substrate-containing polymer, TGase substrate-containing monomer, method for producing protein-polymer complex, and method for improving protein function at solid-liquid interface or in vicinity of solid-liquid interface
#246CAS9 variants and uses thereof
#247Engineered polypeptides having enhanced duration of action and reduced immunogenicity
#248VIRUS-LIKE PARTICLE FOR USE IN IMMUNOASSAY, BLOCKING AGENT FOR USE IN THE IMMUNOASSAY, AND KIT COMPRISING THE VIRUS-LIKE PARTICLE AND THE BLOCKING AGENT
#249Methionyl tRNA synthetase for biosynthesis of photomethionine-labeled protein and method for preparing photoactive protein G variant using same
#250Modified gram positive bacteria and uses thereof
#251GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES
#252Polypeptides
#253Non-Natural Consensus Albumin Binding Domains
#254Vaccine against streptococcal infections based on recombinant proteins
#255Purification of triple helical proteins
#256Vaccine and therapeutic delivery system
#257ORAL ADMINISTRATION
#258Modified pneumolysin (PLY) polypeptides
#259Nucleic acids and proteins from groups A and B
#260Nisin production process
#261Nisin production process
#262Immunogenic proteins and compositions
#263Process of producing a lactate ferment
#264Glycoconjugation process
#265Protein expression enhancing polypeptides
#266ABD binding polypeptide
#267Modular antigen transportation molecules and uses therof
#268Method for the separation of proteins containing an albumin-binding
#269Stabilization of biomimetic membranes
#270PILUS PROTEINS AND COMPOSITIONS
#271Albumin binding polypeptide
#272lactic acid bacterium
#273SCAVENGER CONTAINING PROTEIN FORMED FROM TANDEM-TYPE MULTIMER OF MUTANT EXTRACELLULAR DOMAIN OF PROTEIN G
#274Compositions, methods and uses
#275COMBINATION GAS VACCINES AND THERAPEUTICS
#276Variants of the lantibiotic MU1140 and other lantibiotics with improved pharmacological properties and structural features
#277Biofilm prevention, disruption and treatment with bacteriophage lysin
#278ORAL ADMINISTRATION
#279Spider silk fusion protein structures without repetitive fragment for binding to an organic target
#280Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics
#281Replacement therapy for dental caries
#282Anti-tumor necrosis factor-alpha agents and uses thereof
#283Genome engineering
#284Genome engineering
#285GAS57 mutant antigens and GAS57 antibodies
#286Streptococcus pyogenes antigens and corresponding DNA fragments
#287CHOLERA TOXIN CHIMERA AND ITS USE AS A STAPH VACCINE
#288Polypeptides binding to human complement C5
#289PROTECTIVE VACCINE BASED ON STAPHYLOCOCCUS AUREUS SA2074 PROTEIN
#290Polypeptides targeting glycosylated MUC2 proteins, methods of synthesis, their nucleic acids and uses thereof
#291Competence stimulating peptide
#292TARGET-SPECIFIC PROBE COMPRISING FERRITIN PROTEIN AND DETECTION FOR BIOMARKER USING THE SAME
#293Immunogenic compositions and methods therefor
#294METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN
#295STREPTOCOCCAL GlcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
#296ENGINEERED POYPEPTIDES HAVING ENHANCED DURATION OF ACTION AND REDUCED IMMUNOGENICITY
#297Group A streptococcal M-related proteins and methods of use
#298Modified gram positive bacteria and uses thereof
#299NOVEL MODIFIED PROTEIN COMPRISING TANDEM-TYPE MULTIMER OF MUTANT EXTRACELLULAR DOMAIN OF PROTEIN G
#300Group A multivalent vaccine